Summary
32 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Revenue grew by 8.2% a year over the last 3 years.
What to watch
- Operating profit does not even cover the interest on its debt.
- It reports a profit, yet spends more cash than it brings in.
- It earns only 1.8 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 47.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 1.0% a year over 5 years. Over the last 3 years it grew by 8.2% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 91 USD
- Sales and administration 7.0 USD
- Taxes and other 0.6 USD
- Net profit 1.2 USD
Net profit, industry median (Chemicals - Specialty) 5.9 USD
Out of every 100 USD of revenue, 1.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.71%
- Paid out of profit
- 34%
You receive $0.06 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.